Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral
administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected,
NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or
Lopinavir based HAART-regimen